Immunotherapy for Pleural Mesothelioma.
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of pleural mesothelioma (PM) over the past decade. Although robust data support the use of second-line immunotherapy after first-line chemotherapy, there is a paucity of evidence regarding the efficacy of chemotherapy following frontline ICI.
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of pleural mesothelioma (PM) over the past decade. Although robust data support the use of second-line immunotherapy after first-line chemotherapy, there is a paucity of evidence regarding the efficacy of chemotherapy following frontline ICI.
What the study was
- Study design
- Phase III clinical trial
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Journal of the National Comprehensive Cancer Network : JNCCN
Why it surfaced
Phase III clinical trial in Early cancer detection|Precision oncology and genomic medicine|Novel therapeutics: immunotherapy, CAR-T, targeted therapy; species: mixed; scored 8/10 (novelty=3, relevance=3, design=2, pop=0)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.